Dear All: CARB-X is looking for you! This new job was just now posted: The Director of R&D is a new senior role on the leadership team of CARB-X, reporting directly to the Executive Director (Kevin Outterson). Here’s the brief: “The Director of R&D will take responsibility for the planning, review, awarding and monitoring of novel R&D projects
Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support
Dear All: The Cystic Fibrosis Foundation (CFF) has a standing list of funding opportunities (link), including an annual cycle to fund new therapeutics (link). CFF have now teamed up with CARB-X to host a live webinar on June 11, from 10:00am – 11:00am ET, to introduce their new Infection Research Initiative. There’s not much detail on this
Aside: There is now an application link for the Mar 2020 Antibacterial R&D GRC meeting. See calendar listing below my signature! Dear All: CARB-X this week announced its 2019 calls for proposals (link). There are four application rounds: Non-traditional approaches: Funding Round 1 will be open for Expressions of Interest June 3 – June 10, 2019, 5 PM
Dear All: Two interesting job posts this week. Could one of them be for you? First, CARB-X seeks a Boston-based full-time Chief of R&D (link). This is clearly a very senior role on the CARB-X leadership team: the R&D Chief would have responsibility across the entire CARB-X portfolio for the planning, review, awarding and monitoring of
Dear All, Two things on a Friday afternoon: First,CARB-X Funding Round 4 will be open from 12-19 Nov 2019 for Expressions of Interest (EOIs). This round is very focused and seeks only applications for new classes and/or new targets in early development phases (hit-to-lead through Phase 1) targeting a specific list of Gram-negative pathogens (see link,
Dear All, Committing serial email this afternoon… First, the note I just sent on FMT for Clostridium difficile (link) prompted comments that the organism is now called Clostridioides difficile. This name change slipped past me, I’ll admit! But it does seem a settled change … see this helpful editorial from May 2019 in Lancet ID for a summary of how the new
Note: The fabulous ICARe course organized since 2016 by Patrice Courvalin is urgently seeking additional sources of funding. This one-week intensive residential program is the only soup-to-nuts training program in all things AMR on the planet and routinely gets rave reviews for its content as well as the way it creates fruitful collaborations (and job opportunities). If you know of avenues for support for this extraordinary
Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both
Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list… CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds,
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust